MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc.

MRM
MEDIROM Healthcare Technologies Inc.US flagNASDAQ Capital Market
0.99
USD
+0.01
- -
5.03MMarket Cap
MEDIROM Healthcare Technologies Inc.
MRM
(NASDAQ Capital Market)

Recent

price

0.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
FRC
711.9
810.42
692.92
1,109.16
1,425.77
1,398.45
- -
Revenue per Share
13.75
3.59
-111.8
-203.13
30.54
23.64
- -
Basic EPS, GAAP
19.03
-2.41
-97.57
-137.58
-174.72
-318.23
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-99.02
-22.85
-108.63
-301.55
-271.01
20.54
- -
Book Value per Share
-53.46
92.1
50.37
-245.97
-205.55
-243.58
- -
Tangible Book Value per Share
5
5
5
5
5
5
- -
Basic Weighted Avg Shares
3,433
3,908
3,342
5,410
6,954
6,828
8,299
Sales/Revenue/Turnover
3.32
2.02
-15.8
-7.02
1.69
-5.42
0.22
Operating Margin (%)
44
46
62
126
184
253
290
Depreciation Expense
66
17
-539
-991
149
115
149
Net Income, GAAP
27.47
48.76
- -
- -
17.14
- -
- -
Effective Tax Rate (%)
1.93
0.44
-16.14
-18.31
2.14
1.69
1.79
Profit Margin (%)
-1,417
-884
-565
-1,814
-1,279
-1,802
-1,475
Working Capital
1,667
1,287
1,661
1,875
2,362
2,385
2,052
LT Debt
-118
600
491
-208
-59
216
1,188
Total Equity
- -
1.42
- -
- -
3.33
- -
- -
Return on Invested Capital (%)
- -
1.05
- -
- -
9.72
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
43.63
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-49.12%
450.13%
Free Cash Flow
- -
825.8%
22.06%
Net Income, GAAP
- -
-647.04%
28.91%
Sales/Revenue/Turnover
- -
19.13%
21.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
6,954
2023
- -
- -
- -
- -
6,828
2024
- -
- -
- -
- -
8,299

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
30.54
2023
- -
- -
- -
- -
23.64
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Business
MEDIROM Healthcare Technologies Inc. provides holistic health services in Japan through three primary segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty; the Relaxation Salon segment develops, owns, operates, franchises, and supports salons offering finger-pressure style bodywork therapy, stretch therapy, posture and joint alignment, physical therapy elements, anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology under the Re.Ra.Ku and Ruam Ruam brands; the Digital Preventative Healthcare segment delivers government-sponsored Specific Health Guidance programs via the Lav on-demand health monitoring smartphone application, MOTHER Bracelet wearable fitness and health tracker, REMONY remote monitoring system, and preventative services utilizing nutritionists and health nurses; and the Luxury Beauty segment manages hair salons under the ZACC brand. The company, founded in 2000 and headquartered at 2-3-1 Daiba, Minato-ku, Tokyo, Japan, primarily serves individual consumers and corporate clients across industries such as nursing care, transportation, construction, manufacturing, and government entities including the Japan Ground Self-Defense Force, with operations concentrated in Japan and aspirations for global expansion as a healthcare general trading company. Recent developments include the acquisition of a rehabilitation business from Y's, Inc. in July 2024, a share transfer agreement in June 2024 to acquire 70% of Japan Gene Medicine Corporation with an option for the remaining 30%, a memorandum of understanding in March 2024 for further share acquisition of Japan Gene Medicine, collaboration with Hakuhodo Inc. in July 2025 to join the World Network proof-of-human protocol co-founded by Sam Altman, adoption of REMONY by the Japan Ground Self-Defense Force and certification by the Ministry of Land, Infrastructure, Transport and Tourism as a fatigue-driving prevention device, surpassing 100 contracted companies and 10,000 supported individuals for Lav Specific Health Guidance services, internal investment in subsidiary MEDIROM MOTHER Labs Inc. at a JPY9 billion Series A valuation, and regaining NASDAQ compliance.

Company News

APIChatGPT
  • MEDIROM MOTHER Labs Expands Deployment of "REMONY®" Remote Health Monitoring System in JGSDF 8th Division

  • Micromem Technologies Inc. Update on Wearable Sensing Platform for Defence and Security Application Evaluation

  • Micromem Closes Private Placement

  • MEDIROM Group Reports Q1 2026 Results

  • Medirom Healthcare Technologies (NASDAQ:MRM) Shares Down 2.4% – Here’s What Happened

  • MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations

  • MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity

  • MEDIROM Healthcare Technologies (NYSE:MRM) Shares Down 2.7% – What’s Next?

  • Critical Comparison: Regis (NASDAQ:RGS) and Medirom Healthcare Technologies (NASDAQ:MRM)

  • Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

  • World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku's “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months

  • Financial Contrast: Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)

  • Comparing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)

  • Analyzing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)

  • MEDIROM Partners with World on Technology Envisioned by Sam Altman and Alex Blania: Deploying “Proof of Human” Infrastructure throughout Japan

  • Critical Analysis: Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS)

  • MEDIROM Partners with World

  • Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS) Head-To-Head Analysis

  • Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

  • MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors